Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt

Acta Radiologica

Volumn 53, Issue 5, 2012, Pages 545-550

  Kang, Ji Won ^a   Kim, Jin Hyoung ^a   Ko, Gi Young ^a   Gwon, Dong Il ^a   Yoon, Hyun Ki ^a   Sung, Kyu Bo ^a  

^a Asan Medical Center   (South Korea)

Author keywords

Chemoembolization; Interventional; Liver

Indexed keywords

BLOOD FLOW; CHEMOEMBOLIZATION; CIS-PLATIN; COX REGRESSION ANALYSIS; GELATIN SPONGE; HEPATOCELLULAR CARCINOMA; INTERVENTIONAL; MEDIAN SURVIVAL; PROGNOSTIC FACTORS; TRANSARTERIAL CHEMOEMBOLIZATION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TUMOR RESPONSE;

HEMODYNAMICS; LIVER; PLATINUM COMPOUNDS; REGRESSION ANALYSIS; TUMORS;

PATIENT TREATMENT;

CISPLATIN; ETHIODIZED OIL; GELATIN SPONGE;

ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTERVENTIONAL RADIOLOGY; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER TUMOR; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STENT; SURVIVAL RATE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; ETHIODIZED OIL; FEMALE; GELATIN SPONGE, ABSORBABLE; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOGRAPHY, INTERVENTIONAL; STENTS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84861899021     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2012.110476     Document Type: Article

References (37)

1. Luca A, D'Amico G, La Galla R, et al. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology 1999;212:411-21 (Pubitemid 29356561)
2. Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-47 (Pubitemid 35408308)
3. Banares R, Nunez O, Escudero M, et al. Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology 2005;41:566-71 (Pubitemid 40289504)
4. Elizalde JI, Castells A, Planas R, et al. Prevalence of hepatocellular carcinoma in cirrhotic patients with portosystemic shunt. Cohort analysis. Gastroenterol Hepatol 1996;19:189-93
5. Perarnau JM, Sunyach H, Watelet J, et al. Epidermiology of hepatocellular carcinoma (HCC) in transjugular intrahepatic portosystemic shunt (TIPS) patients. Hepatology 1996;24 (Suppl 1):474A
6. Tesdal IK, Wikstrom M, Flechtenmacher C, et al. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol 2006;29:778-84 (Pubitemid 44128009)
7. Sakaguchi H, Uchida H, Maeda M, et al. Combined transjugular intrahepatic portosystemic shunt and segmental lipiodol hepatic artery embolization for the treatment of esophagogastric varices and hepatocellular carcinoma in patients with cirrhosis: Preliminary report. Cardiovasc Intervent Radiol 1995;18:9-15
8. Serafini FM, Zwiebel B, Black TJ, et al. Transjugular intrahepatic portasystemic stent shunt in the treatment of variceal bleeding in hepatocellular carcinoma. Dig Dis Sci 1997;42:59-65 (Pubitemid 27059922)
9. Hu HT, Kim JH, Lee LS, et al. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol 2011;22:917-23
10. Kim JH, Yoon HK, Ko GY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 2010;255:270-7
11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60
12. Brown DB, Gould JE, Gervais DA, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009;20:S425-34
13. Yang L, Zhang XM, Zhou XP, et al. Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization. J Vasc Interv Radiol 2010;21:1841-6
14. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24 (Pubitemid 34183954)
15. Yuen MF, Cheng CC, Lauder IJ, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5 (Pubitemid 30078596)
16. Seki A, Hori S, Kobayashi K, et al. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: sngle-center experience. Cardiovasc Interv Radiol 2011;34:557-65
17. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002;359:1734-9 (Pubitemid 34607087)
18. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71 (Pubitemid 34454013)
19. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009;10:425-34
20. Chung JW, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198:33-40
21. Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 1994;19:1513-7
22. Kang BK, Kim JH, Kim KM, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma after attempted portal vein embolization in 25 patients. Am J Roentgenol 2009;193:W446-51
23. Kothary N, Weintraub JL, Susman J, et al. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 2007;18:1517-27
24. Kim JH, Yoon HK, Kim SY, et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009;29:1291-8
25. Bonekamp S, Jolepalem P, Lazo M, et al. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 2011;260:752-61
26. Vogl TJ, Nour-Eldin NE, Emad-Eldin S, et al. Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol 2011;17:1267-75
27. Murata S, Tajima H, Nakazawa K, et al. Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts. Eur Radiol 2009;19:2016-23
28. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-9 (Pubitemid 44142456)
29. Brown DB, Chapman WC, Cook RD, et al. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. Am J Roentgenol 2008;190:608-15 (Pubitemid 351304502)
30. Buijs M, Vossen JA, Frangakis C, et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single center experience. Radiology 2008;249:346-54
31. Haskal ZJ, Pentecost MJ, Soulen MC, et al. Transjugular intrahepatic portosystemic shunt stenosis and revision: early and midterm results. Am J Roentgenol 1994;163:439-44 (Pubitemid 24242536)
32. Nazarian GK, Ferral H, Castaneda-Zuniga WR, et al. Development of stenoses in transjugular intrahepatic portosystemic shunts. Radiology 1994;192:231-4 (Pubitemid 24191550)
33. Sterling KM, Darcy MD. Stenosis of transjugular intrahepatic portosystemic shunts: presentation and management. Am J Roentgenol 1997;168:239-44 (Pubitemid 27014781)
34. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004;126:469-75 (Pubitemid 38182304)
35. Rossi P, Salvatori FM, Fanelli F, et al. Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology 2004;231:820-30 (Pubitemid 38668104)
36. Jirkovsky V, Fejfar T, Safka V, et al. Influence of the secondary deployment of expanded polytetrafluoroethylene-covered stent grafts on maintenance of transjugular intrahepatic portosystemic shunt patency. J Vasc Interv Radiol 2011;22:55-60
37. Tesdal IK, Filser T, Weiss C, et al. Transjugular intrahepatic portosystemic shunts: adjunctive embolotherapy of gastroesophageal collateral vessels in the prevention of variceal rebleeding. Radiology 2005;236:360-7 (Pubitemid 40853335)